NCT00139698

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 410 (planned)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	olmesartan alone or in combination with hydrochlorothiazide

Timeline

• Start date: 2005-09-01
• Completion: 2006-07-01
• First posted: 2005-08-31
• Last updated: 2018-12-05

Locations

32 sites across 10 countries: Colombia, Ecuador, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Turkey (Türkiye)